Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 16, 2025

InVivoMab anti-human PD-L1 (B7-H1)

RRID:AB_2687808
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0285, RRID:AB_2687808)

Antibody Information

URL: http://antibodyregistry.org/AB_2687808

Proper Citation: (Bio X Cell Cat# BE0285, RRID:AB_2687808)

Target Antigen: PD-L1 (B7-H1)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vitro PD-L1 blockade, Functional assays, Immunohistochemistry (frozen), Flow cytometry

Antibody Name: InVivoMab anti-human PD-L1 (B7-H1)

Description: This monoclonal targets PD-L1 (B7-H1)

Target Organism: human

Clone ID: clone 29E.2A3

Antibody ID: AB_2687808

Vendor: Bio X Cell

Catalog Number: BE0285

Alternative Catalog Numbers: BE0285-1MG, BE0285-5MG, BE0285-50MG, BE0285-100MG, BE0285-25MG

Record Creation Time: 20231110T034040+0000

Record Last Update: 20240725T004007+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-human PD-L1 (B7-H1).

No alerts have been found for InVivoMab anti-human PD-L1 (B7-H1).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Pal R, et al. (2024) Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity. Cancer research.

Rebeck ON, et al. (2024) A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden. Cell chemical biology.

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer cell, 42(6), 985.

Cheng Y, et al. (2023) High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine, 4(10), 101214.

Wang J, et al. (2023) Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes. iScience, 26(12), 108414.

Chen H, et al. (2023) EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression. Cancer immunology research, 11(6), 830.

Bailey C, et al. (2023) Genetic and pharmaceutical targeting of HIF1? allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease. Cell reports. Medicine, 4(11), 101236.

Weed DT, et al. (2023) The Tumor Immune Microenvironment Architecture Correlates with Risk of Recurrence in Head and Neck Squamous Cell Carcinoma. Cancer research, 83(23), 3886.

Guo D, et al. (2022) Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I?B?. Cell metabolism, 34(9), 1312.

O'Connor RA, et al. (2021) T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer. Oncoimmunology, 10(1), 1940675.

Byun JK, et al. (2020) Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity. Molecular cell, 80(4), 592.

Su S, et al. (2018) Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell, 175(2), 442.